-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Early Detection & Screening
-
Expanding the Role of Neoadjuvant Chemoimmunotherapy in Borderline Resectable Stage III NSCLC
Dr. Biagio Ricciuti says the findings from a recently published study evaluating neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy suggest that chemoimmunotherapy can effectively downstage borderline resectable tumors and enable curative-intent surgery in patients who might otherwise be treated with definitive chemoradiotherapy alone.
-
Dose Escalation Trial Yields Encouraging Results for SCLC With DLL3 Expression
Dr. Julien Mazières reported that while obrixtamig plus ezabenlimab showed encouraging responses at the clinically effective dose, efficacy peaked at the highest dose, reaching an ORR of 58% and a DCR of 83%.
-
Session to Address New Realities, Unique Patient Needs in Lung Cancer Care
On Thursday at ELCC 2026, Dr. Narjust Florez will emphasize the importance of earlier diagnosis and personalized support for younger patients with lung cancer.
-
National Report Shows Rising Lung Cancer Survival Rates but Gaps in Early Detection
The ALA’s 2025 State of Lung Cancer report highlights survival gains while revealing persistent disparities in diagnosis, treatment, and access to biomarker testing.
-
Lung Cancer is Treatable When Found Early. So Why Don’t We Screen Everyone?
Advocate and survivor Jan Pezarro details how investing in a universal age-based lung cancer screening model can save both lives and health care costs.
-
Challenging the Smoking Status Quo: Making the Case for Non-Anatomical Factors to Refine Lung Cancer Staging
Using the IASLC 9th Edition Staging Database, Dr. Lawson Eng and colleagues evaluated the association between smoking status at diagnosis and OS.
-
New Data Warrant Broader Lung Cancer Screening Guidelines
Dr. Elaine Shum said the FANSS trial data confirm the feasibility of expanding screening to high-risk individuals with no smoking history.
-
Survival Benefit Found in Screening Surgically Fit Patients Up to Age 80
Findings from Dr. Patrick Goodley suggest that older patients who can undergo surgery may achieve survival benefits similar to younger patients.
-
Smoking Cessation in Lung Cancer Screening: The Latest Randomized Controlled Trial Evidence
The SCALE trials aim to uncover key elements of successful smoking cessation programs by evaluating various intervention combinations.
-
Where There’s Smoke: The Global Threat of Lung Cancer in Patients with No Smoking History and its Implications in Screening
Dr. Lucia Viola says that access to genomic profiling is crucial for gathering information about patients who do not smoke.